Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 21.03
(2.14%)
CNY 21.03
(2.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.24 Billion CNY | -7181.47% |
| 2022 | 17.51 Million CNY | -92.5% |
| 2021 | 233.57 Million CNY | -7.62% |
| 2020 | 252.84 Million CNY | 12.23% |
| 2019 | 225.28 Million CNY | 60.93% |
| 2018 | 139.98 Million CNY | -28.91% |
| 2017 | 196.91 Million CNY | 12.21% |
| 2016 | 175.48 Million CNY | 12.28% |
| 2015 | 156.29 Million CNY | 16.87% |
| 2014 | 133.73 Million CNY | 16.1% |
| 2013 | 115.18 Million CNY | 16.24% |
| 2012 | 99.08 Million CNY | 39.96% |
| 2011 | 70.79 Million CNY | 17.63% |
| 2010 | 60.19 Million CNY | 65.52% |
| 2009 | 36.36 Million CNY | 291.73% |
| 2008 | 9.28 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 14.76 Million CNY | 123.94% |
| 2024 Q3 | 54.19 Million CNY | 267.1% |
| 2024 Q1 | -61.66 Million CNY | 92.76% |
| 2023 Q1 | 4.54 Million CNY | 109.12% |
| 2023 Q2 | -160.41 Million CNY | -3632.32% |
| 2023 FY | -1.24 Billion CNY | -7181.47% |
| 2023 Q3 | -232.45 Million CNY | -44.9% |
| 2023 Q4 | -851.88 Million CNY | -266.48% |
| 2022 Q3 | 2.52 Million CNY | -92.8% |
| 2022 FY | 17.51 Million CNY | -92.5% |
| 2022 Q4 | -49.77 Million CNY | -2068.73% |
| 2022 Q2 | 35.1 Million CNY | 18.41% |
| 2022 Q1 | 29.65 Million CNY | 11.94% |
| 2021 Q1 | 68.56 Million CNY | 42.19% |
| 2021 FY | 233.57 Million CNY | -7.62% |
| 2021 Q3 | 50.12 Million CNY | -43.29% |
| 2021 Q2 | 88.39 Million CNY | 28.92% |
| 2021 Q4 | 26.48 Million CNY | -47.16% |
| 2020 FY | 252.84 Million CNY | 12.23% |
| 2020 Q1 | 48.78 Million CNY | 57.1% |
| 2020 Q4 | 48.22 Million CNY | -34.81% |
| 2020 Q3 | 73.96 Million CNY | -9.66% |
| 2020 Q2 | 81.87 Million CNY | 67.84% |
| 2019 Q2 | 66.62 Million CNY | 17.59% |
| 2019 FY | 225.28 Million CNY | 60.93% |
| 2019 Q1 | 56.65 Million CNY | 369.88% |
| 2019 Q3 | 70.95 Million CNY | 6.51% |
| 2019 Q4 | 31.05 Million CNY | -56.24% |
| 2018 Q1 | 45.37 Million CNY | -29.18% |
| 2018 Q2 | 60.71 Million CNY | 33.79% |
| 2018 Q4 | -20.99 Million CNY | -138.25% |
| 2018 Q3 | 54.88 Million CNY | -9.6% |
| 2018 FY | 139.98 Million CNY | -28.91% |
| 2017 Q3 | 49.26 Million CNY | 21.41% |
| 2017 FY | 196.91 Million CNY | 12.21% |
| 2017 Q1 | 42.99 Million CNY | -42.79% |
| 2017 Q4 | 64.08 Million CNY | 30.07% |
| 2017 Q2 | 40.57 Million CNY | -5.62% |
| 2016 Q4 | 75.14 Million CNY | 138.11% |
| 2016 FY | 175.48 Million CNY | 12.28% |
| 2016 Q1 | 28.89 Million CNY | -58.82% |
| 2016 Q3 | 31.56 Million CNY | -20.86% |
| 2016 Q2 | 39.88 Million CNY | 38.01% |
| 2015 Q1 | 24.05 Million CNY | -60.68% |
| 2015 Q4 | 70.17 Million CNY | 166.64% |
| 2015 Q3 | 26.31 Million CNY | -26.36% |
| 2015 Q2 | 35.74 Million CNY | 48.59% |
| 2015 FY | 156.29 Million CNY | 16.87% |
| 2014 Q4 | 61.18 Million CNY | 233.98% |
| 2014 FY | 133.73 Million CNY | 16.1% |
| 2014 Q1 | 22.45 Million CNY | -51.77% |
| 2014 Q2 | 31.77 Million CNY | 41.5% |
| 2014 Q3 | 18.31 Million CNY | -42.34% |
| 2013 Q4 | 46.55 Million CNY | 205.41% |
| 2013 FY | 115.18 Million CNY | 16.24% |
| 2013 Q1 | 21.47 Million CNY | -47.62% |
| 2013 Q2 | 31.9 Million CNY | 48.61% |
| 2013 Q3 | 15.24 Million CNY | -52.22% |
| 2012 Q3 | 12.21 Million CNY | -54.31% |
| 2012 Q2 | 26.72 Million CNY | 39.53% |
| 2012 Q1 | 19.15 Million CNY | -12.93% |
| 2012 FY | 99.08 Million CNY | 39.96% |
| 2012 Q4 | 40.98 Million CNY | 235.61% |
| 2011 Q3 | 6.85 Million CNY | -74.22% |
| 2011 Q4 | 21.99 Million CNY | 220.9% |
| 2011 FY | 70.79 Million CNY | 17.63% |
| 2011 Q2 | 26.59 Million CNY | 73.27% |
| 2011 Q1 | 15.34 Million CNY | -20.78% |
| 2010 Q3 | 12.61 Million CNY | 0.0% |
| 2010 FY | 60.19 Million CNY | 65.52% |
| 2010 Q4 | 19.37 Million CNY | 53.63% |
| 2009 FY | 36.36 Million CNY | 291.73% |
| 2008 FY | 9.28 Million CNY | 0.0% |